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Abstract
Background: In order to promote consumer-oriented informed medical decision-making
regarding screening mammography, we created a decision model to predict the age dependence of
the cancer detection rate, the recall rate and the secondary performance measures (positive
predictive values, total intervention rate, and positive biopsy fraction) for a baseline mammogram.
Methods: We constructed a decision tree to model the possible outcomes of a baseline screening
mammogram in women ages 35 to 65. We compared the single baseline screening mammogram
decision with the no screening alternative. We used the Surveillance Epidemiology and End Results
national cancer database as the primary input to estimate cancer prevalence. For other
probabilities, the model used population-based estimates for screening mammography accuracy
and diagnostic mammography outcomes specific to baseline exams. We varied radiologist
performance for screening accuracy.
Results: The cancer detection rate increases from 1.9/1000 at age 40 to 7.2/1000 at age 50 to 15.1/
1000 at age 60. The recall rate remains relatively stable at 142–157/1000, which varies from 73–
236/1000 at age 50 depending on radiologist performance. The positive predictive value of a
screening mammogram increases from 1.3% at age 40 to 9.8% at age 60, while the positive
predictive value of a diagnostic mammogram varies from 2.9% at age 40 to 19.2% at age 60. The
model predicts the total intervention rate = 0.013*AGE2 - 0.67*AGE + 40, or 34/1000 at age 40 to
47/1000 at age 60. Therefore, the positive biopsy (intervention) fraction varies from 6% at age 40
to 32% at age 60.
Conclusion: Breast cancer prevalence, the cancer detection rate, and all secondary screening
mammography performance measures increase substantially with age.

Background
Analysts have debated the benefits and harms of screening
mammography in the medical literature for over a decade
[1-3]. The 1997 National Institutes of Health Consensus
Conference concluded that younger women should

decide for themselves whether and when to begin screening. Physicians must therefore understand breast cancer
risk and the accuracy and consequences of screening in
order to help women make that decision [4]. Analysts,
advocates and critics of screening mammography
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acknowledge the need for informed medical decisionmaking (IMDM) [5-7]. Recently, the American College of
Physicians has advocated informed decision-making concerning screening mammography for women under 50
[8]. However, analysts have not applied the tool of decision analysis to study the initial or baseline screening
mammogram.
Women desire accurate information from their physicians
about the benefits, limitations, and potential harms of
screening mammography before their baseline exam. Furthermore, 90% want involvement in the screening decision [9], while 80% are confident in their decisionmaking ability if presented with relevant information
[10]. The fact that this information has not been effectively communicated raises ethical questions regarding
the biased promotion of screening mammography [11].
For example, in one survey 60% of U.S. women believed
that mammography prevents or reduces the risk of contracting breast cancer, rather than the risk of dying from
breast cancer [12]. In reality, the development risk for
breast cancer is probably higher with mammography due
to ionizing radiation [5,13]. Two studies showed that only
around 5% of women are aware of the existence of ductal
carcinoma in situ (DCIS) or nonprogressive cancers
[14,15]. Furthermore, 85% of women think that mammography seldom misses cancers [15].
Since a woman's decision to obtain a baseline mammogram is an independent first step in the screening process,
we used decision analysis to model the possible outcomes
of the baseline screening mammogram as a starting point
to help educate women and promote consumer-oriented
medical care. A recent Institute of Medicine report stressed
the importance of publicizing three screening mammography performance measures, including the cancer detection rate (CDR), the recall rate, and the positive biopsy
fraction (PBF) [16]. Consequently, we used the decision
model to predict how these primary events and secondary
performance measures change as a function of age.

Methods
Decision model
Screening mammography by definition involves only
women without any breast symptoms that might indicate
that cancer is present [17]. A baseline mammogram is the
first screening mammogram a woman obtains. The radiologist reading the mammogram looks for evidence of
breast cancer including masses and small calcifications. If
no suspicious findings are present, the radiologist recommends routine screening to check for the interval development of cancer. The next screening mammogram a
woman obtains is a subsequent mammogram, which the
radiologist compares with the baseline mammogram if
available. If the radiologist sees suspicious findings on a
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baseline or subsequent screening mammogram, the
woman returns for a diagnostic mammogram or ultrasound to determine if the findings are more likely from
breast cancer or more likely from normal variation. After
the diagnostic imaging, the radiologist may recommend
that the woman return to routine screening, receive a
short-term follow-up mammogram, or consult with a
breast surgeon for clinical evaluation and possible imageguided or surgical biopsy of the suspicious findings on the
mammogram.
Decision analysis applies quantitative methods to help
optimize decision making under uncertainty, with applications in diagnostic radiology [18]. We created a decision
tree that models a simplified screening scenario starting
with the choice that a woman faces starting in her late thirties: either to start screening for breast cancer and begin
with a baseline screening mammogram, or postpone
screening by doing nothing, as shown by the decision
node square in Figure 1. The first branch point (probability node circles) of each decision splits into women with
and without cancer, while the second branch point for
those getting screening splits into a positive or negative
mammogram, with terminal outcome nodes (triangles)
for those with cancer. The third branch point includes
diagnostic and subsequent imaging, consultations, and
interventions for healthy women. We did not include
likely stages of diagnosis or the effects of overdiagnosis
since they do not affect the calculation of the performance
measures. To keep the model simple and easier to comprehend, we did not simulate the effects of repeat screening. We used DATA™ 3.5 software (TreeAge,
Williamstown, MA, 1999) and Excel (Microsoft, Redmond WA, 2003) to construct the computer model.
To summarize the model inputs, the first branch point
probability node uses age-dependent population-based
estimates for breast cancer prevalence. We derived the
prevalence values from the Surveillance Epidemiology
and End Results (SEER) program age-specific incidence
rates 1998–2002 [19], as shown in Table 1[20-23]. The
second branch point probability nodes use populationbased estimates for screening mammography diagnostic
accuracy (sensitivity and specificity) as the major input.
Table 2 shows the most recent relevant published accuracy
data from the Breast Cancer Surveillance Consortium
(BCSC) [24-26], which are derived by using the Breast
Imaging Reporting and Data System (BI-RADS) categories
[27]. We used published intermediate and final outcomes
specific to baseline exams for the healthy women third
branch point probability nodes, while we derived the
fourth branch point probability node value from published total biopsy rates. We describe all derivations in
detail at the end of the Methods section.
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Decision
Figure 1model for baseline screening mammography used to predict primary and secondary performance measures
Decision model for baseline screening mammography used to predict primary and secondary performance
measures. An asymptomatic woman between ages 35 and 65 getting a baseline mammogram faces four possible outcomes.
These outcomes depend on her health status (cancer or healthy) and the initial radiologist reading (positive or negative). The
corresponding inputs for the circular probability nodes are population-based values of age-dependent cancer prevalence and
radiologist accuracy. There is a wide range of radiologist performance for sensitivity and specificity. The probability of a truepositive outcome is equivalent to the cancer detection rate, a screening benefit. The false-positive outcome involves healthy
women and is a screening harm. Besides additional diagnostic imaging, this outcome may result in further diagnostic evaluation
and intervention. The probability values for the third and fourth branch points (BiR12initial, etc.) use population-based data.

The screening mammogram can have four possible outcomes: true-positive, false-negative, true-negative, and
false-positive, from which the model predicts the two primary events CDR and recall rate. For example, the recall
rate includes all women called back for additional imaging evaluation based on the initial radiologist reading of a
positive screening mammogram, and these exams could
be true-positive (cancer) or false-positive (healthy). The
model calculates the predicted secondary performance
measures using the primary events and the distal branches
of the false-positive outcome screening mammogram.

Model predictions: performance measures
As shown in Figure 1, screening mammograms in women
with cancer (D+) are classified as either true-positive cases
(TP) or false-negative cases (FN), so D+ = TP + FN. Mammograms in healthy women (D-) may be either true-negative cases (TN) or false-positive cases (FP), so D- = TN +
FP [28,29]. The probability of a true-positive outcome for
all screened women, shown as the top 3rd division branch
of the decision tree in Figure 1, equals sensitivity (TP/
(TP+FN)) times prevalence (a proportion, or D+/1000
screens), or TP cases/1000 screens. We can also define the
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Table 1: Breast cancer incidence rates and estimated prevalence.

Age

35.0
37.5
40.0
42.5
45.0
47.5
50.0
52.5
55.0
57.5
60.0
62.5
65.0

Invasive*

DCIS†

Total

DCIS

Sojourn Prevalence‡ Low§ High

Annual incidence per
1000 women

Annual incidence per
1000 women

Annual incidence per
1000 women

% of all breast cancer Years

Cases/1000

0.44
0.62
0.91
1.20
1.58
1.95
2.25
2.56
2.96
3.36
3.65
3.95
4.18

0.07
0.11
0.24
0.36
0.48
0.60
0.70
0.80
0.86
0.92
0.95
0.97
1.00

0.51
0.73
1.15
1.57
2.06
2.55
2.95
3.36
3.82
4.28
4.60
4.92
5.18

14
15
21
23
23
24
24
24
23
22
21
20
19

1.03
1.46
2.30
3.24
4.39
6.08
7.78
9.68
11.97
14.56
16.86
19.34
21.76

2.0
2.0
2.0
2.1
2.2
2.4
2.7
2.9
3.1
3.4
3.7
3.9
4.2

2.9
3.9
5.3
6.7
8.1
9.9
12.1

3.7
4.9
7.0
9.0
11.3
14.1
17.2

* Incidence rate data from SEER 1998–2002. [19]
† Ductal carcinoma in situ.
‡ Prevalence is incidence rate (Invasive + DCIS) times sojourn time. [20-23]
§ Low and high ranges apply the low and high values for sojourn time.

sensitivity as the true-positive fraction, or TPF [30]. Likewise, the probability of a false-positive outcome or FP
cases/1000 screens equals [1 – specificity] times [1 – prevalence]. Overall specificity is defined by the true-negative
fraction, or TN/(TN + FP), with the complement the falsepositive fraction (FPF), or 1-specificity = FP/(TN +FP). In
our model, the sum of the probabilities of true-positive
outcomes, false-negative outcomes, true-negative outcomes, and false-positive outcomes is equal to one.
We calculated the primary events including the CDR and
the recall rate from the four possible mammography outcomes as follows. The CDR, defined as cancers detected
per 1000 women screened [16], is equivalent to the probability of a true-positive outcome, or TP cases/1000
screens. The BCSC definition of CDR = TP/(TP + FN + TN
+ FP), where the denominator equals all cases or all
women screened (D+ plus D-) [26]. In our model, the
recall rate or abnormal interpretation rate equals the sum
of the initial radiologist readings of positive cases/1000
screens [16], or the probability of a true-positive outcome
plus the probability of a false-positive outcome. We can
convert the recall rate to a percentage of all screens by
dividing the numerator by ten.
We calculated the secondary performance measures
including predictive values as follows. The positive predictive value of a screening mammogram (PPVS) is a proportion (TP/(TP + FP)) [16], and equals the CDR divided by
the recall rate [31]. Likewise, the negative predictive value
of a screening mammogram is a proportion that equals
the TN cases/1000 screens (specificity times [1-prevalence]), divided by the sum of the negative cases/1000

screens. The positive predictive value of a diagnostic
mammogram (PPVD) following an abnormal screening
mammogram is the CDR divided by the sum of the CDR
and the healthy women diagnostic evaluation rate (a percentage of the probability of a false-positive outcome, the
bottom 3rd division branch). The total intervention rate
(TIR) is the healthy women intervention rate (a percentage of the diagnostic evaluation rate) plus the CDR
(women with cancer intervention rate). Finally, the PBF is
the CDR divided by the total intervention rate.
To simplify our results in order to support IMDM, we generated scatter plots of incidence and prevalence and each
model prediction versus age in Excel (Microsoft, Redmond WA, 2003). We determined the best-fitting trend
line by simple linear regression as defined by highest coefficient of variation (R2) for each model outcome, with a
linear fit for recall rate and negative predictive value for
simplicity. For comparison purposes, we took available
updated but unpublished data from the BCSC website
(available at http://breastscreening.cancer.gov/) for
women with no previous mammography from 1996 to
2005 for 5-year age groups 40–44 through 60–64 including the CDR, recall rate, and PPVS. We used the BCSC cancer rate by age to compare with our input prevalence [32].
We also used the most recently published BCSC data for
the CDR, recall rate and PPVS for age groups 40–49 and
50–59 [25].
Sensitivity analysis
To estimate the effect of radiologist variability including
the callback threshold (sensitivity/specificity pair) as well
as skill level, we calculated a range of values for the model
Page 4 of 16
(page number not for citation purposes)

BMC Medical Informatics and Decision Making 2008, 8:40

http://www.biomedcentral.com/1472-6947/8/40

Table 2: Breast Cancer Surveillance Consortium (BCSC) recent studies of screening mammography accuracy.

Parameter

Value†

Sensitivity*

71.3%
53%
82.1%
61%
92.1%
68%
89.3%
66%
68.2%
70.7%
78.1%
79.7%
88.6%
76.8%
77.8%
65.3%
53.8%
85.9%
92.5%
92.1%
90.5%
93.3%

Specificity||

Range‡

Ages

Period§

Previous exams

Years

< 40

1
2
1
2
1
2
1
2
1
1
1
1
1
1
1
2
2
1
1
1
2
2

No

1996–01

40–49
50–59
60–69

85.8–91.4
75.7–77.9
77.6–78.0

85.6–86.1
0.0
91.9–92.3

< 40
40–49
50–59
60–69
40–89
40–89
40–89
40–89
40–89
40–89
40–89
40–89
40–89
40–89

No
No
No
Yes
Yes
Yes
Yes
No
Yes
Both
None past 5 yrs
Yes
No
Yes
Both
None past 5 yrs
Yes

1996–00

1996–99
1996–00

1996–99

* Positive exam is Breast Imaging Reporting and Data System (BI-RADS)[27] category 0, 4, 5, and category 3 if there is immediate diagnostic
evaluation.[26]
† The first four age-dependent one-year baseline sensitivity values are from reference [25]. The matching two-year values also used in the model are
derived (see text). Matching one-year previous mammography sensitivity values are provided for comparison from reference [25].
‡ Ranges are 95% confidence intervals available only for one-year accuracy values ages 40–89 from reference [26].
§ Time frame for calculating sensitivity and specificity. Two-year accuracy values for ages 40–89 are from reference [24].
|| The one-year specificity values are from reference [26]. The baseline specificity value is used in the model for all age groups.

output. We took the BCSC radiologist performance sensitivity and specificity at the 10th and 90th percentiles and
adjusted our values by the ratio of these outliers to the
median [32]. For example, the BCSC 90th percentile for
sensitivity is 89.3; the median is 81.3, giving a ratio of
1.0984. Likewise, the 10th percentile ratio is 0.8303 (67.5/
81.3). For specificity, we adjusted the FPF, or 1-specificity,
in a similar manner, so that the 90th percentile ratio of performance is 0.481 (5.1/10.6), while the 10th percentile
ratio is 1.632 (17.3/10.6). We assumed these ratios were
constant across all ages. Therefore, the CDR directly
reflects variation in sensitivity. However, since the recall
rate and all other performance measures use both the
CDR and the FPF, we assumed that a reader with low specificity (high FPF) would also read at high sensitivity
(high TPF), as supported by BCSC data [33].
Model inputs: probability nodes
First branch point: prevalence
Prevalence is the percentage of the population possessing
a disease at a given point in time. The incidence rate is the
number of new cases that develop over a specific period.
A baseline exam will identify undetected prevalent disease. Prevalence approximately equals the incidence rate

times the average duration of disease [20]. Assuming
screening could start somewhere between ages 35 and 65,
we derived prevalence input data for the model using the
SEER program age-specific incidence rates for both DCIS
and invasive cancer from 1998 to 2002 [19]. In the case of
screening of asymptomatic women, the average duration
of disease is the preclinical mammography detectable
state, or the period of time (sojourn) during which imaging can theoretically detect a cancer but before a woman
has symptoms [21].
We assumed an average sojourn time by combining estimates of sojourn time from three screening mammography trials including Canada, Stockholm, and Swedish
Two-County. We calculated an estimate of 2.13 years for
ages 40–49 ((1.9+2.1+2.4)/3), and 3.13 years for ages 50–
59 (2.6+3.1+3.7)/3), and the single value of 4.2 years for
ages 60–69 [22,23]. We applied these values at ages 45
and 55 and 65 and used linear interpolation to derive the
remaining values. We also assumed a base value of 2.0 for
ages 35–40. Under these assumptions, Table 1 shows the
calculated breast cancer prevalence per 1000 women. For
comparison purposes, we calculated a reasonable low and
high range for prevalence using the range of sojourn times
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at 45 and 55 and repeated interpolation. However, we did
not vary the model input prevalence due to lack of ranges
for younger and older women and in order to emphasize
the effect of radiologist accuracy on the model predictions.
Second branch point: accuracy
Table 2 includes baseline and subsequent screening mammography sensitivity and specificity from the BCSC published literature, which reflects the United States
population. We considered a screening mammogram a
positive test result (versus negative) if the radiologist's
assessment led to immediate further evaluation, which
includes BI-RADS category 0, 4, or 5, or a 3 with recommendation for additional diagnostic imaging or surgical
consultation [26]. For BI-RADS audit comparison purposes, mammography sensitivity is typically (and arbitrarily) defined as the number of patients diagnosed with
cancer within one year of a positive mammogram, divided
by all screened patients with a diagnosis of cancer over
one year [27]. From a practical standpoint, less than 5%
of United States mammography facilities have the means
to keep track of false-negative results by linking mammograms to breast cancers [16]. However, the BCSC has this
ability and uses the BI-RADS audit definitions of accuracy
when collecting its data [31].

We also derived a two-year sensitivity because two years is
both close to the sojourn time period of preclinical
detectability and the time interval recommended for
screening by an advisory panel [34]. Two years gives more
time for cancers not identified at mammography (assuming they were detectable) to present themselves, so the
two-year sensitivity will be lower [35]. However, some
slower-growing cancers present at the initial screening
mammogram will not become apparent. Therefore, we
can make an argument for a three-year sensitivity based
on sojourn times for women over 50, but as the measuring period increases, the chance increases that faster-growing cancers that were not detectable would be counted as
not identified.
We derived the age-dependent two-year sensitivity by
using the most recently published BCSC age-dependent
one-year values of 71–92% for women with no previous
mammogram shown in Table 2[25]. We multiplied this
value by the two-year to one-year sensitivity ratio using
BCSC data for women ages 40–89, or 65.3/88.6 = 74%.
This ratio is close to the Canada, Stockholm, and Swedish
Two-County screening mammography trials first-round
screen ratio of ((0.67+0.79+0.91)/3), or 79% [36]. Application of the BCSC ratio gives a two-year sensitivity value
of 53% (0.74*71.3) for women under age 40, 61%
(0.74*82.1) for women ages 40–49, 68% (0.74*92.1) for
women ages 50–59, and 66% (0.74*89.3) for women
ages 60–69. Comparison with previous BCSC studies

http://www.biomedcentral.com/1472-6947/8/40

shows that sensitivity has improved over time and
increases with age for first screening and subsequent
mammography [37,38]. For subsequent mammography,
sensitivity also increases with lower breast density [39].
Table 2 shows sensitivity for BCSC subsequent mammography is about 85% (54/65, 77/89) of first screening sensitivity, likely due to harder-to-detect smaller tumors [36].
For specificity, we used the BCSC one-year value of 85.9%
for women ages 40–89 (95% CI 85.6–86.1), which is
based on 70,200 first (no previous mammography) mammograms, with 64% of the women under age 50 [26]. Specificity with first screening mammography is stable with
age, and for subsequent mammography increases slightly
from 91% at 40–49 to 93% at 60–69 [38,39]. Furthermore, the one-year specificity value should not vary much
with increasing time with low prevalence of disease [35].
The BCSC recall rate of 14.7% (95% CI 14.4–14.9)
includes the true-positive and false-positive exams, or (TP
+ FP)/(TP + FN + TN + FP) [26]. With low prevalence typical in screening mammography (under 2%), the FPF or
(FP/(TN +FP)) is very close to the recall rate since TP and
FN are relatively small.
Third branch point: intermediate outcomes
Figure 1 shows that women with cancer have the cancer
detected (true-positive) or not (false-negative) depending
on the sensitivity. Healthy women have true-negative or
false-positive mammograms with possible additional
evaluation. We derived probabilities for these outcomes
based on BCSC data for 119,000 first mammography
exams (no history of or over 5 years since last mammogram) [24]. Within the true-negative outcome (85.9%
(specificity) of healthy women), 96% would be complete
(BiR12initial probability), while 4% would face followup exams for stability of the findings in 6 months and 1
and maybe 2 years (BiR3initial probability). For the falsepositive outcome (14.1% of healthy women), women
would be recalled by the radiologist within 90 days to
undergo additional diagnostic imaging, usually unilateral
additional view mammography and/or ultrasound. We
consider this evaluation after a positive screening examination an "indirect" diagnostic mammogram, while a
"direct" diagnostic mammogram follows from the evaluation of a symptomatic breast problem and would have its
own PPVD [40]. After this diagnostic imaging evaluation,
38.2% would be categorized as complete (BiR12final
probability), 16.2% would face follow-up exams
(BiR3final probability), and 45.6% would undergo additional diagnostic evaluation or consultation (BiR045
probability), or 6.4% (14.1*45.6) of the women in the
false-positive branch.
Fourth branch point: intervention rate
We assumed 50% of these healthy women would have a
surgical consultation followed by a clinical follow-up
Page 6 of 16
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examination (BiR0final probability). The other 50%
(BiR45final probability) would have a surgical consultation followed by an intervention, including tissue biopsy
or fine-needle aspiration (FNA). This probability assumption allows correlation with published total (cancer and
benign) intervention rates and predicts a healthy women
(benign) intervention rate after baseline screening of
32.1/1000 at age 40 to 31.6/1000 at age 60. We decided
to use the PBF instead of the positive predictive value of a
recommended biopsy (BI-RADS 4 and 5), since we
assumed women would care more about actual chances of
an intervention. In actual practice, about one-third of
BCSC tracked biopsies occur after a BI-RADS 1, 2 or 3 classification [41]. We defined the PBF denominator to
include all interventions, including FNA.
We obtained total intervention rates from the BCSC and
the National Breast and Cervical Cancer Early Detection
Program (NBCCEDP) for first screening mammograms,
the latter targeting low-income women. In one analysis of
both programs from 1996 to 1999, first screening mammograms were described as mammograms among
women with no previous mammogram in the database
and no self-reported mammogram within 5 years. Recommended biopsy rates were 24.4/1000 (95% CI 23.0–26.0)
for BCSC first screening mammograms for women over
age 50 and were 9.9/1000 (95% CI 9.7–10.2) for subsequent mammograms, for a first/subsequent ratio of 2.4.
The recommended rates and the total open biopsy fraction increased slightly with age. The results for the NBCCEDP were 31/1000 (95% CI 30–32) [42]. These results
included FNA, so the recommended biopsy rate equals
the recommended intervention rate.
The BCSC total recommended tissue biopsy rate from
1996 to 2001 was 12.7/1000, following mostly subsequent (93%) but including baseline mammograms. The
biopsies reported and performed within one year were
16.1/1000, giving a reported/recommended tissue biopsy
ratio of 1.27 (16.1/12.7). These tissue biopsy rates were
constant for ages 40–89. Since about 32% of the BCSC
recommended biopsies had no pathology results
reported, although they were likely performed (or had
FNA), true intervention rates are likely higher than the
reported performed results of 16.1/1000 by an additional
(12.7/1000 *0.32) = 4.1/1000 [41]. This means true intervention rates could be from 16.1/1000 (reported) to 20.2/
1000 (reported plus assumed performed), giving a ratio of
1.25. The estimated PBF is 15.6% (1612/10346) at ages
40–49 and 26.6% (2470/9283) at 50–59 if we apply the
1.25 multiplier to the benign tissue biopsies. Finally, we
multiplied the subsequent mammography intervention
rates by the first/subsequent ratio of 2.4 for women over
50 to estimate the total intervention rate for a baseline
mammogram of 38–48/1000.
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We also used an updated analysis of the NBCCEDP from
1995 to 2002, which excluded women with symptoms
(about 11%) in a subset of the analysis. There were
703,000 baseline exams, defined as first program screening mammograms regardless of previous reported history
of mammography. For example, the CDR for ages 40–49
was 4.0/1000 and the total biopsy rate (without FNA) was
26.1/1000 [43], which would increase to 31.3/1000
assuming a multiplier of 1.2 for FNA was applied. This
multiplier is from an academic medical center with an
overall intervention rate of 16.8/1000 [44]. Therefore, taking the CDR and dividing by the intervention rate gives a
PBF of 12.8% (4.0/31.3) for 40–49, and values of 18.9%
(5.3/28.1) for 50–59, and 26.7% (7.5/28.1) for 60–64.
Including women with symptoms for ages 40–49
increased the CDR to 8.9/1000 and the total biopsy rate to
40.0/1000, which would limit the use of the NBCCEDP
data for other performance parameters. The low-income
status of the participants also would likely make these
intervention rates less representative compared to an
insured population.

Results
Figures 2 and 3 show the model-predicted primary events
(CDR and recall rate) associated with baseline mammography, while Figures 4 and 5 summarize predicted secondary performance measures. Table 3 shows the regression
equations for incidence, prevalence and model predictions with the associated R2 value. The increase in CDR
with age generally tracks the prevalence 2nd order polynomial, while the recall rate is linear and stable with age.
Both the primary events and the secondary performance
measures have a wide range of values depending on radiologist performance at the 10th or 90th percentiles. Specificity dominates the recall rate by an order of magnitude:
the false-positive outcomes (140/1000) and recall rate
(147/1000) at age 50 are about 20 times the CDR (7.2/
1000). At age 50, the recall rate range from 10th to 90th percentile is 16.3%, but this decreases only to 16.1% when
using a median sensitivity at the extremes of specificity.
Therefore, equal absolute percentage changes in radiologist sensitivity or specificity would have disparate effects.
Figure 4 shows how the PPVS and PPVD increase with age.
The reciprocal of the predicted value, or the number of
screening recall mammograms or positive diagnostic
mammograms needed to detect a cancer, consequently
decreases with age. The average PPVS or CDR/recall rate at
age 50 is 4.9% (range 3.3–8.1), and the reciprocal is 20
screening positives/cancer. A radiologist skilled in finding
breast cancer but with average specificity would improve
PPVS at age 50 to 5.3%, but a radiologist skilled in calling
normal as normal but with average sensitivity would have
a PPVS of 9.6%. This doubling highlights the primary
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Table 3: Best-fit equations for model predictions.

Model Input*

Equation

R2

Incidence
Prevalence
Model Output
Cancer detection rate 1 year
Recall rate
PPV†, screening
NPV‡, screening
PPV†, diagnostic
Total intervention rate
Positive biopsy fraction

y = 0.165*AGE - 5.37
y = 0.016*AGE2 - 0.90*AGE + 12.54

0.996
0.998

y = 0.013*AGE2 - 0.70*AGE + 8.26
y = 0.054*AGE + 12.08
y = 0.007*AGE2 - 0.31*AGE + 2.18
y = -0.007*AGE + 100.2
y = 0.011*AGE2 - 0.30*AGE - 2.51
y = 0.013*AGE2 - 0.67*AGE + 39.98
y = 0.01*AGE2 + 0.29*AGE - 21.85

0.996
0.957
0.995
0.814
0.994
0.996
0.992

* Values from Table 1.
† PPV = Positive predictive value.
‡ NPV = Negative predictive value.

importance of specificity in improving secondary performance measures.
Figure 5 also shows that the predicted total baseline mammogram intervention rate for women over 50 varies from
39/1000 at age 50 to 51/1000 at age 65. The PBF at age 45

of 10% (range 7–16) is lower than the NBCCEDP
(12.8%) and BCSC modified (15.6%) values, while the
PBF of 26% at age 55 (range 19–38) is closer to the corresponding values of 19% and 27%. The negative predictive
value of a screening mammogram varies from 99.95% at
age 40 to 99.93% at age 50 and 99.79% at age 60. The low

Cancer detection rate/1000

25

20

15
Predicted CDR 1yr
Predicted CDR 2yr
10

5

0
35 37.5 40 42.5 45 47.5 50 52.5 55 57.5 60 62.5 65
Woman's age - years
Figure 2 baseline screening mammography primary performance measure: cancer detection rate (CDR)
Predicted
Predicted baseline screening mammography primary performance measure: cancer detection rate (CDR). The
probability of a true-positive outcome is equivalent to the CDR, or breast cancers detected per 1000 screening mammograms
for women ages 35–65. We calculated the CDR using both one-year and two-year sensitivity estimates with no range assumed
for prevalence. Sensitivity is the probability that a radiologist interprets a mammogram as positive in screened women who
have a cancer diagnosis over one or two years of follow-up. The 90th (high error bars) and 10th (low error bars) percentile of
radiologist performance for sensitivity generates the range around the one year predictions.
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30

Recall rate (%)

25

20
Predicted RR%
RR% with SIFE

15

10

5

0
35 37.5 40 42.5 45 47.5 50 52.5 55 57.5 60 62.5 65
Woman's age - years
Figure 3 baseline screening mammography primary performance measure: recall rate (RR)
Predicted
Predicted baseline screening mammography primary performance measure: recall rate (RR). The RR percentage
is recalls per 100 (not 1000) screening mammograms for women ages 35–65. Women both with and without cancer are
recalled for further diagnostic imaging of abnormalities seen on the initial positive screening mammogram. The 10th/90th (high
error bars) and 90th/10th (low error bars) percentile of radiologist performance for specificity/sensitivity generates the range
around the RR predictions. Specificity is the fraction of negative mammograms in women who remain healthy over one year of
follow-up. SIFE are short interval follow-up mammogram examinations without additional diagnostic imaging.

prevalence and high specificity overwhelm the effect of
sensitivity: at age 50 and 10% sensitivity, the negative predictive value drops to only 99.2%.
Table 4 summarizes the actual BCSC cancer rates and
selected performance measures as percentages of the
model input incidence, prevalence and corresponding
model output predictions. The actual BCSC cancer rate at
9–15 months averages 115% of the model input SEER
incidence data. However, the actual BCSC first mammography cancer rate varies between 55% and 77% of the
model input prevalence, mean 66%. Even when using the
low range of sojourn time, which decreases the model
input, the mean is 81%. Consequently, the actual BCSC
CDR is below the predicted CDR on average about 72%
using one-year sensitivity, and 98% using two-year sensitivity. The actual BCSC recall rate averages 96% of the predicted recall rate, which implies the specificity in the
model is reasonably accurate. The actual BCSC PPVS averages 71% of the predicted PPVS, again reflecting the lower
actual cancer rate.

Discussion
We have constructed a decision model of screening mammography using population-based parameters that allows
reasonable prediction of baseline primary events and secondary performance measures. We found that the recall
percentage is generally stable with age at about 15%
(range 7–24%), with women facing an overall recall of
about 18% (including short-interval follow-up imaging),
with a 14% chance of an immediate false-positive exam.
Our decision model predicts how the CDR and PBF generally track the increasing prevalence of breast cancer with
age: a 50-year-old woman has 3.4 times the prevalence of
a 40 year old, while the predicted CDR and PBF are 3.8
and 3.3 times as high, respectively.
Our model predicts how starting screening at age 45 or 55
would considerably improve overall baseline mammography secondary performance measures simply because
breast cancer is relatively more common and easier to
detect as women age, while recall rates are stable. The
increasing CDR means the absolute benefit from baseline

Page 9 of 16
(page number not for citation purposes)

BMC Medical Informatics and Decision Making 2008, 8:40

http://www.biomedcentral.com/1472-6947/8/40

40

Positive predictive value (%)

35
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Predicted PPVS%
Predicted PPVD%

20
15
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0
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PPVD)
Figure
Predicted
4 secondary performance measures: positive predictive values for screening and diagnostic mammograms (PPVS,
Predicted secondary performance measures: positive predictive values for screening and diagnostic mammograms (PPVS, PPVD). Increasing cancer prevalence and screening sensitivity with age mean radiologists detect more cancers and the potential absolute benefit of baseline mammography increases with age. Recall exams are mostly false-positive
mammograms, which cause unwanted collateral costs from screening. The relative stability of the recall rate makes the positive
predictive value performance measures increase with age. The reciprocal of the positive predictive value is the number of
screening recall mammograms or positive diagnostic mammograms needed to detect a cancer.

screening increases with age, given the potential lifeextending benefit from earlier detection and treatment
through delaying or preventing advanced disease. However, the recall rate which is mostly unwanted (collateral)
false-positive exams in healthy women (95% at age 50, or
1 – PPVS) is relatively stable with age. So the potential
benefit/collateral cost ratio gradually increases with age
[6], as shown by the increasing PPVS, PPVD and PBF values.
In reality, the major screening problem of overdiagnosis,
or the detection of nonprogressive or nonlethal pseudodisease, complicates this simplified economic analysis
[21]. Overdiagnosis leads to harmful overtreatment and
associated anxiety without any potential benefit to the
woman [45,46]. The source of the absolute benefit from
screening is the earlier detection of and effective intervention for some otherwise lethal tumors. The absolute risk
reduction is equal to the relative risk reduction times the
absolute death risk. If the relative risk reduction from

screening is constant, the increasing age-dependent absolute death risk determines the absolute benefit [47]. The
breast-cancer deaths prevented by screening translated
into the age-dependent discounted years of life saved will
ultimately reflect the absolute benefit [48]. Consequently,
the CDR as a performance measure directly reflects the
development risk for breast cancer, but only indirectly
reflects the absolute benefit of screening mammography.
Adjusting the CDR to reflect the proportion of lives saved
among the women with mammography-detected cancers
may present a more realistic benefit. We have estimated
this proportion to be under 5% [49,50]. Breast cancer is a
heterogeneous disease, with grades of metastatic potential
and length of sojourn time [51]. Screening also has a limited window for possible effectiveness and may work only
when the detection occurs before the critical point (development of metastases), and if both events occur during
the sojourn time [21]. Earlier detection will not extend
lives if the critical time point occurs after the onset of
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Total intervention rate/1000 and PBF (%)
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Figure 5 secondary performance measures: total intervention rate and positive biopsy fraction (TIR, PBF)
Predicted
Predicted secondary performance measures: total intervention rate and positive biopsy fraction (TIR, PBF).
The TIR is for 1000 screening mammograms for women ages 35–65 and includes the interventions of tissue biopsy and needle
aspiration. The PBF percentage is a widely accepted performance measure due to the desire to avoid the high financial and
emotional cost and invasive nature of negative interventions. The model predicts that the PBF does not reach the minimum
recommended level of 25% until age 55. Stratifying the recommendations for screening so that only higher risk women would
be encouraged to screen at younger ages would increase the prevalence and therefore improve all performance measures.

breast symptoms, or before the breast cancer is detectable
by imaging. In less lethal cancer (including pseudodisease), the critical time point may be delayed or never
occur. Detecting a cancer early can also cause harm: earlier
intervention associated with mammography appears to
activate dormant metastases in some cases, especially in
younger women [52].
Clinical implications
Stratifying the recommendations for screening so that
only higher-risk women would be encouraged to screen
earlier or more often would increase the prevalence and
therefore improve performance measures [53,54]. Recent
research on risk stratification for breast cancer shows this
approach may be practical to increase screening efficiency
[55]. Notably, performance measures are worse in women
under age 50: 39% of all diagnostic mammograms after

screening occur in this group [40], but less than 25% of
invasive cancers do [53]. A screening "cost-effectiveness"
proxy is the negative biopsy fraction (1-PBF), since a negative intervention incurs high financial and emotional
costs due to its invasive nature without a corresponding
potential benefit of cancer detection. Our model predicts
that the negative biopsy fraction is over 90% (range 84–
93%) for women under 45 and does not approach performance benchmarks of 60–75% [27,40] until after age
55. As shown in Figure 5, even the best United States radiologists will not achieve a level of 75% until women reach
age 49.
Consequently, United States organizations [2] and other
countries [56,57] have varied opinions regarding the
appropriate age to begin and way to practice screening.
For instance, the United Kingdom screens women ages 50
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Table 4: Screening mammography BCSC performance data.*

AGE

42.5

BCSC CANCER RATE/1000, 9–15 Months†
Percent of model input incidence‡
BCSC CANCER RATE/1000, No Previous§
Percent of model input prevalence‡ (high-low)
BCSC CANCER DETECTION RATE/1000
% 1 year sensitivity
% 2 year sensitivity
BCSC RECALL RATE/1000¶
Percent of model
BCSC PPVS**, %
Percent of model

2.25
144
2.49
77 (67–86)
2.00
75
102
123
86
1.6
86

45

47.5

3.40||
94
128
143||
99
2.0||
80

2.98
117
4.39
72 (63–83)
3.75
75
102
149
103
2.5
73

50

52.5
3.66
109
5.73
59 (51–70)
5.11
57
78
151
102
3.3
55

55

57.5

8.36||
76
103
156||
104
4.9||
67

4.44
104
9.99
69 (58–83)
9.32
70
94
147
96
6.3
72

60

62.5
5.08
103
10.64
55
9.55
55
75
132
85
7.2
65

* Data available at Breast Cancer Surveillance Consortium (BCSC) website using screening examinations from 1996–2005.[32]
† Months since previous mammography.[26]
‡ Prevalence and incidence rates are taken from Table 1.
§ No previous mammography or first mammography.[26]
|| Published performance data for 40–49 and 50–59 age groups.[25]
¶ Recall for diagnostic imaging occurs within 90 days after the initial screening exam.
** Positive predictive value of a screening mammogram, which arithmetically equals the cancer detection rate/recall rate.[26]

to 70 with a screening interval of 3 years, with about half
the recall rate but similar cancer detection rates compared
with the United States for baseline and subsequent exams
[42,58]. Therefore, United Kingdom performance measures should be higher. The European desirable recall rate
is under 5% for a baseline exam (and under 3% for a subsequent exam), which is also half the 10% United States
guideline for all mammograms [31]. Analysis of BCSC
data shows the United States desirable recall rate should
be no more than 10% for baseline and 6.7% for subsequent exams [25]. These recommendations and practices
may reflect differences in practice environments and radiologist skill. However, using a broader economic perspective, these targets should reflect an analysis of the
opportunity cost of resources devoted to screening and
diagnosis versus the absolute net benefit of lives saved
minus screening harms. Unfortunately, screening advocates have exaggerated this net benefit through the
emphasis on relative rather than absolute risk reduction
with screening and the failure to discuss mammography
harms in many scientific articles [11].
The principle of IMDM decentralizes this debate and
helps each woman instead of a "policymaker" or potentially biased "expert" decide what starting age is best for
her regarding screening [59]. However, the woman must
understand the benefits and harms as well as the true
opportunity cost of screening mammography [5,60,61].
Although age is the most important risk factor for breast
cancer development, most women are unaware of this fact
[62]. Women tend to identify genetics as paramount, yet
only 10% of all breast cancer patients have a family history of first-degree relative (mother, sister, and daughter)
with cancer [53]. To stress the importance of age, perhaps
decision aids could present risk as an equivalent risk-

adjusted age for breast cancer development [63]. In this
way, a higher risk woman could anticipate mammography performance as equivalent to that for an older
woman.
Since the appropriate contents of a screening decision
guide are debatable, research is needed on applying these
results and making decision guides easier for physicians to
present and for women and the public to understand
[53,64,65]. For example, a decision guide for younger
women utilizes a simplified decision tree of breast-cancer
screening [66,67]. Including discussion of DCIS overdiagnosis and the accuracy limitations of mammography,
which result in false-positive follow-up testing and associated psychological costs, would improve this type of decision guide [68]. Explaining that "peace of mind" after a
negative mammogram [15] is more a function of low
prevalence than the sensitivity of the baseline exam would
also promote realistic expectations.
Model applications
Besides being an education tool, we can use our model to
predict the effect of new technology on performance
measures [69]. For example, the true value of computeraided detection (CADe) for mammography depends on
the overall marginal effect on both CDR, or (sensitivity
times prevalence); and the recall rate = (CDR + ([1-specificity] times [1-prevalence])) [49,70]. Our model shows
how both the CDR and FP cases/1000 screens influence
the other performance measures. For example, the BCSC
CADe study showed relative increases in sensitivity (84.0/
80.4) and decreases in specificity (87.2/90.2). Using these
same relative changes, our model predicts for 50-year-old
women an increase of 29% in the recall rate (32% actual),
a drop of 19% in the PPVS (22% actual), an increase of
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26% in the TIR (20% actual), and a drop of 17% in the
PBF [71]. The secondary performance measures will be
stable only if there are equal relative percentage changes
in both the CDR and FP cases/1000 screens.
Receiver operating characteristic analysis computes the
inverse relationship and inherent trade-off between sensitivity (TPF) and specificity (1-FPF) given the natural overlap between diseased and healthy individuals,
independent of prevalence. In theory, when prevalence is
incorporated and costs of decision consequences are computed, the optimal threshold or sensitivity/specificity pair
on any receiver operating characteristic curve can be calculated [30]. We used our model to predict how the recommended threshold for screening mammography varies
with age or risk. The optimal operating points appear
closer to European than United States recommendations,
but depend on multiple assumptions including false-positive exam resource costs and the value assigned to a year
of life saved [72].
Limitations
Our analysis is limited to the decision to undergo a baseline exam, the first step in screening mammography.
There is an obvious benefit of higher specificity and
reduced false-positive recalls in subsequent mammography when prior mammograms are available, although
specificity will also drop as sensitivity increases with
decreasing frequency of screening [26]. Complete evaluation of age-related screening performance would require
modeling the effects of both initial and repeat screening
over multiple periods and frequencies of screening [73].
However, these models must choose an arbitrary period
for repeated screening as well as mortality benefit assumptions [74].

Furthermore, a comprehensive model may be less useful
for education purposes. Our single mammogram model
focusing on performance measures helps quantify the primary importance of age. A woman makes the decision to
screen independently each time; a woman cannot buy a
coupon worth seven screens over the next decade. The fact
is that many women undergo sporadic screening and
ignore recommendations. For instance, mammography
registry data and models show that although 75% of
women age 40 to 50 have obtained a baseline mammogram, over 43% have a gap time of over 2.5 years, and
only 24% get an annual mammogram [75,76].
The cancer detection rates for the baseline exam predicted
from our model are higher than the actual BCSC cancer
detection rates because the model input prevalence is
higher: both sensitivity values use the same BCSC data.
However, these BCSC and NBCCEDP first mammograms
may not be truly baseline and may underestimate true

http://www.biomedcentral.com/1472-6947/8/40

prevalence as shown by the differences in cancer rates. The
fact that the 9–15 months actual BCSC data are close to
the SEER incidence rates implies that the BCSC has biased
data for first mammography, especially for younger
women, or that the sojourn estimates are biased. Our
sojourn time estimates could be too long; this could occur
with overdiagnosis [22]. Furthermore, SEER incidence
data is an average and based on all cancer diagnoses, and
screened and non-screened women with cancer could
have different incident rates. The higher predicted CDR
from our model is conservative in that it will result in
higher predicted PPV performance measures in Figures 4
and 5.
Consequently, we could improve our model with better
estimates of risk-adjustable prevalence and sojourn time,
as well as baseline total intervention rates. Although our
model also uses older accuracy data that does not include
recent digital technology, the effect should be minimal. In
one large trial, digital mammography had no overall accuracy benefit compared to film, but digital did have
increased sensitivity and receiver operating characteristic
curve accuracy benefits in the single subset of women
under 50 with dense breasts (17% of participants, digital
1.25 year sensitivity 59% versus film 27%) [77]. But since
most digital units have CADe technology [78], any combined digital/CADe claim for accuracy gain is problematic
because CADe causes decreased receiver operating characteristic curve accuracy [71]. The excess false-positive
recalls due to CADe's influence on the radiologist calling
a normal mammogram abnormal (computer-aided
deception) overwhelms the benefit (extra cancer detection). As our model predicts, false-positive recall exams
should increase substantially with combined digital/
CADe mammography [79].
Finally, the CDR is a limited performance measure for
radiologists due to the influence of age-related prevalence:
as Figure 2 shows, the 90th percentile (highly skilled) radiologist reading mammograms for women age 50 will find
fewer cancers than the 10th percentile radiologist reading
mammograms for women age 55. Emphasizing the CDR
also reinforces the naïve but widely held notion that
breast cancer is a homogeneous disease [15], and therefore the belief that earlier detection is always helpful. For
instance, in one cross-sectional survey, 94% of women
thought that a woman with screen-detected cancer "may
have benefited from the mammograms" [14]. Consequently, to support IMDM and professional honesty
[80,81], radiologists should continually emphasize to the
public that the correct scenario is "earlier cancer detection
saves some lives-but screening harms healthy women" or
"mammography might extend your life-but often misses
cancers."
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Conclusion
By applying decision analysis, we have modeled the consequences of the single baseline screening mammography
decision as a function of age and predicted the CDR, recall
rate, and various positive predictive values. The principle
of IMDM requires that women be educated about mammography accuracy limitations and the substantial age
dependence of cancer incidence rates and prevalence, and
consequently baseline screening mammography primary
and secondary performance measures.
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